Tranexamic Acid-13C2,15N

An internal standard for the quantification of tranexamic acid

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥8100.00

6480.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Tranexamic acid 13C2,15N is intended for use as an internal standard for the quantification of tranexamic acid by GC- or LC-MS. Tranexamic acid is an inhibitor of fibrinolysis that inhibits the interaction of plasmin with fibrin (IC50 = 3.1 μM in isolated human plasma).1 It reduces increases in the expression of the profibrogenic genes Timp1 and Col1a1, but not Itgb6, Tgfβ1, or Tgfβ2, and increases in hepatic protein levels of cytokeratin 19 (CK19) and type I collagen induced by α-naphthylisothiocyanate (AINT) after 28 days in a mouse model of chronic bile duct injury.2

|1. Bostr?m, J., Grant, J.A., Fjellstr?m, O., et al. Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J. Med. Chem. 56(8), 3273-3280 (2013).|2. Joshi, N., Kopec, A.K., Towery, K., et al. The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. J. Pharmacol. Exp. Ther. 349(3), 383-392 (2014).